Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21791984 | 0.97 | TSHR (0.33) | TSHR | |
| SCHEMBL3504741 | 0.90 | — | — | |
| SCHEMBL21791973 | 0.90 | — | — | |
| SCHEMBL12677822 | 0.87 | — | — | |
| SCHEMBL21791978 | 0.86 | — | — | |
| SCHEMBL21791976 | 0.79 | — | — | |
| SCHEMBL21791981 | 0.79 | — | — | |
| SCHEMBL12677829 | 0.67 | TSHR (0.31) | TSHR | |
| Cyclopropane SCHEMBL9251557 | 0.65 | — | — | |
| SCHEMBL11365619 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11043374-B2 | Silacycloalkane compounds and methods for depositing silicon containing films using same | VERSUM MATERIALS US, LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200075323-A1 | Silacycloalkane Compounds And Methods For Depositing Silicon Containing Films Using Same | VERSUM MATERIALS US, LLC (US) | 2020-03-05 | — | — | US | disclosed |
| US-8273726-B2 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | BRANDEIS UNIVERSITY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100184724-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING DISEASES CHARACTERIZED BY THE PRESENCE OF METAL IONS | GRENPHARMA LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-7595308-B2 | Treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using organosilicon compounds such as dichlorodiethylsilane | GRENPHARMA LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090203644-A1 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | GRENPHARMA LLC (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184724-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING DISEASES CHARACTERIZED BY THE PRESENCE OF METAL IONS | FABP2, SLC3A2, SLC40A1 | TSHR 1785/4885 |
| US-11043374-B2 | Silacycloalkane compounds and methods for depositing silicon containing films using same | SIK1, PKN2, PKN1 | TSHR 4881/4885 |
| US-20090203644-A1 | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | APP, PSEN1, IAPP | TSHR 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.